Download PDF
Geburtshilfe Frauenheilkd 2017; 77(01): 66-72
DOI: 10.1055/s-0042-115566
GebFra Science
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study

Der mTOR-Inhibitor Everolimus verringert endometriotische Krankheitsherde: Eine experimentelle Studie an der Ratte
T. Kacan
1   Department of Medical Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey
,
C. Yildiz
2   Department of Obstetrics and Gynecology, Cumhuriyet University School of Medicine, Sivas, Turkey
,
S. Baloglu Kacan
3   Department of Internal Medicine, Sivas Numune Hospital, Sivas, Turkey
,
M. Seker
1   Department of Medical Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey
,
H. Ozer
4   Department of Pathology, Cumhuriyet University School of Medicine, Sivas, Turkey
,
A. Cetin
2   Department of Obstetrics and Gynecology, Cumhuriyet University School of Medicine, Sivas, Turkey
› Author Affiliations
Further Information

Publication History

received 09 June 2016
revised 28 July 2016

accepted 17 August 2016

Publication Date:
30 January 2017 (online)

Also available at
   Permissions and Reprints

Comment on:

mTor Inhibitors for the Treatment of EndometriosisGeburtshilfe Frauenheilkd 2018; 78(03): 283-284
DOI: 10.1055/s-0043-124518

Abstract

Introduction Mammalian target of rapamycin is a pathway to block apoptosis. Recent studies showed that the activity of mammalian target of rapamycin pathway increases in endometriotic lesions. Aim of the present study was to study the effect of everolimus agent, a rapamycin analog, in an experimental endometriosis model.

Materials and Methods Endometriosis established by the autotransplantation of uterine tissue in the peritoneal cavity was confirmed in 24 rats. The animals were then randomly divided into three groups to receive either everolimus (1.5 mg/kg/day, p. o.), anastrozole (0.004 mg/day, p. o.), or normal saline (0.1 mL, i. p.) for 14 days. Endometriotic foci were excised, stained with hematoxylin and eosin, and endometriosis was scored semiquantitatively. In addition, immunohistochemical examination were performed using primary antibodies of vascular endothelial growth factor, CD117, and Bax.

Results Both anastrozole and everolimus lowered endometriosis scores. Significant decreases in ovarian follicles were observed following anastrozole treatment but not everolimus treatment.

Conclusion Through its apoptosis-promoting effect, everolimus suppressed endometriotic foci without negatively affecting ovarian reserve. These findings support the hypothesis that everolimus merits further study on the way to developing a new endometriosis drug.

Zusammenfassung

Einleitung Mammalian Target of Rapamycin (mTOR, deutsch: Ziel des Rapamycins im Säugetier) funktioniert als Signalweg zur Verhinderung von Apoptose. Neue Studien haben gezeigt, dass die Aktivität des mTOR-Signalwegs in endometriotischen Läsionen erhöht ist. Ziel dieser Studie war es, die Auswirkungen von Everolimus, einem Rapamycin-Analogon, in einem experimentellen Endometriosemodell zu studieren.

Material und Methoden Es wurde eine Endometriose durch Autotransplantation von Gebärmuttergewebe in die Bauchhöhle von 24 Ratten hervorgerufen. Das Vorhandensein der Endometriose wurde anschließend überprüft. Die Tiere wurden danach in 3 Gruppen randomisiert und erhielten über 14 Tage hinweg entweder Everolimus (1,5 mg/kg/d, p. o.), Anastrozol (0,004 mg/d, p. o.), oder Kochsalzlösung (0,1 mL, i. p.). Endometriotische Krankheitsherde wurden operativ entfernt, mit Hämatoxylin und Eosin eingefärbt, und das Ausmaß der Endometriose wurde semiquantitativ bewertet. Zusätzlich wurde eine immunhistochemische Analyse mit Primärantikörper von Vascular Endothelial Growth Factor, CD117 und Bax durchgeführt.

Ergebnisse Die Gabe von Anastrozol wie auch von Everolimus verringerte die Endometriosewerte. Nach der Behandlung mit Anastrozol wurde aber ein signifikanter Rückgang ovarieller Follikel vermerkt, der nach einer Behandlung mit Everolimus nicht auftrat.

Schlussfolgerung Die Apoptose-fördernde Wirkung von Everolimus verringerte die endometriotischen Krankheitsherde, ohne dass die ovarielle Reserve negativ beeinflusst wurde. Dieses Ergebnis stützt die Vermutung, dass weitere Studien zur Wirksamkeit von Everolimus als potenzielles Medikament gegen Endometriose nötig sind.

Key words

apoptosis - endometriosis - everolimus - ovarian reserve

Schlüsselwörter

Apoptose - Endometriose - Everolimus - ovarielle Reserve
 

  • References

  • 1 Johnson N, Farquhar C, Crossley S. et al. A double-blind randomised controlled trial of laparoscopic uterine nerve ablation for women with chronic pelvic pain. BJOG 2004; 111: 950-959
    CrossrefPubMedGoogle Scholar
  • 2 Adamson G, Kennedy S, Hummelshoj L. Creating solutions in endometriosis: global collaboration through the World Endometriosis Research Foundation. J Endometriosis 2010; 2: 3-6
    PubMedGoogle Scholar
  • 3 Simoens S, Dunselman G, Dirksen C. et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod 2012; 27: 1292-1299
    CrossrefPubMedGoogle Scholar
  • 4 Platteeuw L, DʼHooghe T. Novel agents for the medical treatment of endometriosis. Curr Opin Obstet Gynecol 2014; 26: 243-252
    CrossrefPubMedGoogle Scholar
  • 5 Braza-Boïls A, Marí-Alexandre J, Gilabert J. et al. MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. Hum Reprod 2014; 29: 978-988
    CrossrefPubMedGoogle Scholar
  • 6 Johnson NP, Hummelshoj L, Abrao M. et al. Consensus on current management of endometriosis. Hum Reprod 2013; 28: 1552-1568
    CrossrefPubMedGoogle Scholar
  • 7 McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45-55
    CrossrefPubMedGoogle Scholar
  • 8 Cinar O, Seval Y, Uz YH. et al. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online 2009; 19: 864-871
    CrossrefPubMedGoogle Scholar
  • 9 Harada T, Kaponis A, Iwabe T. et al. Apoptosis in human endometrium and endometriosis. Hum Reprod Update 2004; 10: 29-38
    CrossrefPubMedGoogle Scholar
  • 10 Leconte M, Nicco C, Ngô C. et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011; 179: 880-889
    CrossrefPubMedGoogle Scholar
  • 11 Ellard SL, Clemons M, Gelmon KA. et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541
    CrossrefPubMedGoogle Scholar
  • 12 Vernon MW, Wilson E. Studies on the surgical induction of endometriosis in the rat. Fertil Steril 1985; 44: 684-694
    PubMedGoogle Scholar
  • 13 Keenan JA, Williams-Boyce PK, Massey PJ. et al. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999; 72: 135-141
    CrossrefPubMedGoogle Scholar
  • 14 Donnez J, Smoes P, Gillerot S. et al. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998; 13: 1686-1690
    CrossrefPubMedGoogle Scholar
  • 15 Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138
    PubMedGoogle Scholar
  • 16 Oral E, Demir B, Inceboz U. Endometriosis and ovarian reserve. Womenʼs Health 2015; 11: 671-675
    PubMedGoogle Scholar
  • 17 Meresman GF, Bilotas M, Abello V. et al. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005; 84: 459-463
    CrossrefPubMedGoogle Scholar
  • 18 Amsterdam LL, Gentry W, Jobanputra S. et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005; 84: 300-304
    CrossrefPubMedGoogle Scholar
  • 19 Yildiz C, Kacan T, Akkar OB. et al. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol 2016; 197: 159-163
    CrossrefPubMedGoogle Scholar
  • 20 Thangavelu A, Hewitt MJ, Quinton ND. et al. Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. Gynecol Oncol 2013; 131: 613-618
    CrossrefPubMedGoogle Scholar
  • 21 Streuli I, de Ziegler D, Santulli P. et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 2013; 14: 291-305
    CrossrefPubMedGoogle Scholar
  • 22 Burgova EN, Tkachev NA, Paklina OV. et al. The effect of dinitrosyl iron complexes with glutathione and S-nitrosoglutathione on the development of experimental endometriosis in rats: a comparative studies. Eur J Pharmacol 2014; 741: 37-44
    CrossrefPubMedGoogle Scholar
  • 23 Matsui H, Asami T. Effects and therapeutic potentials of kisspeptin analogs: regulation of the hypothalamic-pituitary-gonadal axis. Neuroendocrinology 2014; 99: 49-60
    CrossrefPubMedGoogle Scholar
  • 24 Gibran L, Maranhão RC, Abrão MS. et al. Could statins constitute a novel treatment for endometriosis? Systematic review of the literature. Eur J Obstet Gynecol Reprod Biol 2014; 179: 153-158
    CrossrefPubMedGoogle Scholar
  • 25 Wang Y, Lin M, Weng H. et al. ENMD-1068, a protease-activated receptor 2 antagonist, inhibits the development of endometriosis in a mouse model. Am J Obstet Gynecol 2014; 210: 531.e1-531.e8
    CrossrefPubMedGoogle Scholar
  • 26 Santanam N, Kavtaradze N, Murphy A. et al. Antioxidant supplementation reduces endometriosis-related pelvic pain in humans. Transl Res 2013; 161: 189-195
    CrossrefPubMedGoogle Scholar
  • 27 Leavy O. Reproductive immunology: evading immunosurveillance in endometriosis. Nat Rev Immunol 2015; 15: 729-729
    CrossrefPubMedGoogle Scholar
  • 28 Baselga J, Campone M, Piccart M. et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
    CrossrefPubMedGoogle Scholar
  • 29 Franz DN, Belousova E, Sparagana S. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132
    CrossrefPubMedGoogle Scholar
  • 30 Laschke M, Elitzsch A, Scheuer C. et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006; 149: 137-144
    PubMedGoogle Scholar
  • 31 Yagyu T, Tsuji Y, Haruta S. et al. Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer 2006; 16: 1545-1551
    CrossrefPubMedGoogle Scholar
  • 32 Choi J, Jo M, Lee E. et al. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil Steril 2015; 104: 655-664.e1
    CrossrefPubMedGoogle Scholar
  • 33 Wagner S, Dancey JE. Potential future Indication of Rapamycin Analogs for the Treatment of solid Tumors. In: Mita M, Mita A, Rowinsky EK. eds. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Paris: Springer; 2016: 229-249
    Google Scholar
  • 34 Meyer LA, Slomovitz BM, Djordjevic B. et al. The search continues: looking for predictive biomarkers for response to mTOR inhibition in endometrial cancer. Int J Gynecol Cancer 2014; 24: 713
    CrossrefPubMedGoogle Scholar
  • 35 Suo G, Sadarangani A, Tang W. et al. Telomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells. Reprod Sci 2014; 21: 1161-1170
    CrossrefPubMedGoogle Scholar